In August 2025, Terumo Corporation acquired UK-based OrganOx for $1.5 billion. This transaction set a new valuation standard for innovative medical companies, especially those with normothermic organ perfusion (NMP) technology. This event demonstrates that the global market is valuing not only current revenues, but more importantly, the technology’s potential to change the standard of medical care.

NanOX – the next step in the evolution of the NMP

The NanOX project, being developed by NanoGroup, goes a step further. Like OrganOx, NanOX is based on the idea of storing organs under physiological-like conditions. However, it introduces a breakthrough innovation – the proprietary NanOX 4 Kidney synthetic fluid. Unlike blood-based solutions, our fluid contains no leukocytes or pathogens, enhancing safety. It does not require the use of blood co simplifies logistics and will allow for more mass dissemination of perfusion. It also offers some medical advantages due to its greater efficiency in transferring respiratory gases. NanOX focuses on kidneys, the largest segment of transplantation, accounting for 60% of all transplants.

The potential of NanOX

Given its technology profile and alignment with global transplant trends, NanOX has a real opportunity to become an acquisition or partnership target with a global player – just like OrganOx. The acquisition of OrganOx confirms that technological innovations in transplantation that solve key problems can yield multi-billion dollar returns.

We encourage you to read the full analysis in the attached case study.

➡️ CASE STUDY OrganOx – a deal to acquire a disruptive innovation